(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
3 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 5.92%
@ $17.41
Utstedt: 14 feb 2024 @ 20:15
Avkastning: -9.99%
Forrige signal: feb 14 - 19:13
Forrige signal:
Avkastning: 1.58 %
Live Chart Being Loaded With Signals
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens...
Stats | |
---|---|
Dagens volum | 604 700 |
Gjennomsnittsvolum | 1.49M |
Markedsverdi | 972.00M |
EPS | $0 ( 2024-03-20 ) |
Neste inntjeningsdato | ( $-0.640 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 19.35 |
ATR14 | $0.0180 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-04 | Peters Jeffrey Stuart | Sell | 42 500 | Employee stock option (right to buy) |
2024-04-04 | Peters Jeffrey Stuart | Buy | 42 500 | Common Stock |
2024-04-04 | Peters Jeffrey Stuart | Sell | 42 500 | Common Stock |
2024-04-04 | Peters Jeffrey Stuart | Sell | 147 | Common Stock |
2024-04-04 | Peters Jeffrey Stuart | Sell | 232 | Common Stock |
INSIDER POWER |
---|
43.87 |
Last 100 transactions |
Buy: 2 053 694 | Sell: 721 474 |
Volum Korrelasjon
MacroGenics Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
BNIXU | 0.951 |
AVIR | 0.933 |
CGEM | 0.914 |
EWTX | 0.907 |
SRPT | 0.9 |
FSEA | 0.899 |
VSTM | 0.894 |
ROVR | 0.894 |
HCCI | 0.893 |
NPCE | 0.892 |
10 Mest negative korrelasjoner | |
---|---|
CSSEN | -0.908 |
VNET | -0.901 |
KBNT | -0.899 |
CRCT | -0.894 |
KSPN | -0.89 |
AHPI | -0.888 |
VRM | -0.885 |
LHDX | -0.884 |
BSMO | -0.882 |
AXDX | -0.881 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
MacroGenics Inc Korrelasjon - Valuta/Råvare
MacroGenics Inc Økonomi
Annual | 2023 |
Omsetning: | $58.75M |
Bruttogevinst: | $58.13M (98.95 %) |
EPS: | $-0.000100 |
FY | 2023 |
Omsetning: | $58.75M |
Bruttogevinst: | $58.13M (98.95 %) |
EPS: | $-0.000100 |
FY | 2022 |
Omsetning: | $151.94M |
Bruttogevinst: | $144.56M (95.14 %) |
EPS: | $-1.950 |
FY | 2021 |
Omsetning: | $75.64M |
Bruttogevinst: | $72.99M (96.50 %) |
EPS: | $-3.30 |
Financial Reports:
No articles found.
MacroGenics Inc
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.